Two newly tested drugs, Dexamethasone and Remdesivir, have been discovered to both reduce the deaths and hospitality time of seriously ill Coronavirus patients


According to Science News, two new drugs have been discovered to both reduce the deaths and hospitality time of seriously ill Coronavirus patients. Dexamethasone, a corticosteroid, was proven to reduce deaths of COVID-19 patients on ventilators by about a third and deaths of COVID-19 patients on supplemental oxygen by about 20 percent (Medline Plus). Dexamethasone “stops two phases of inflammation and exerts both anti-inflammatory and immunosuppressive effects” in order to prevent COVID-19 from killing seriously ill patients (Medium). In addition to the death-defying drug, Remdesivir was proven to shorten recovery time for seriously ill patients by four days. Remdesivir is an “antiviral drug that works by mimicking building blocks of the coronavirus’s genetic material, RNA. As the virus copies its RNA, Remdesivir takes the place of some building blocks, stopping or slowing viral replication” (Science News). ~

To prove the effects of Dexamethasone, a clinical trial was held including 2,104 patients taking 6 milligrams of dexamethasone once a day for 10 days either as a tablet or by intravenous injection, as well as 4,321 placebo patients, according to New Scientist. Martin Landray, a cardiologist at the University of Oxford, and his colleagues discovered that taking dexamethasone could prevent one death for every eight patients on ventilation, and one death for every 25 patients needing extra oxygen. Remdesivir was also tested in a clinical trial and the results were considered so promising that a safety oversight committee stopped the clinical trial early to give people taking the placebo a chance to get the drug. ~

Although the results are important for treating the sickest patients with COVID-19, those patients represent only about 5 percent of people diagnosed with the coronavirus, says Rajesh Gandhi, an infectious disease doctor at Massachusetts General Hospital and Harvard Medical School in Boston. But, Landray expects doctors around the world to embrace the drugs and that the United Kingdom’s National Health Service may soon declare dexamethasone the standard treatment for people on ventilators because of COVID-19. ~

Leave a Reply